Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedA new revision entry, v3.5.0, has been added to the history, and the entry for v3.4.3 has been removed.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision v3.4.3 was added and Revision v3.4.2 was removed from the version history.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision: v3.4.2 added to the history and the preceding notices about government funding lapse and operating status (v3.4.1) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check60 days agoChange DetectedA site-wide funding notice was added, and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check68 days agoChange DetectedAdditions include Show glossary / Hide glossary controls and color-coded highlights for additions and deletions, plus the new revision note v3.4.0. Deletions remove the No FEAR Act data label and the prior revision note v3.3.4.SummaryDifference0.5%

- Check82 days agoChange DetectedOn 2026-01-07, Contacts/Locations and Study Status were added (revision v3.3.4). On 2025-12-15, revision v3.3.3 was deleted.SummaryDifference0.2%

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.